Plucking up Courage, Beckman Buys Coulter
Executive Summary
Most people thought that the eventual acquirer for Coulter, which had been actively seeking a buyer recently--would be Johnson & Johnson or Roche. That it proved to be Beckman was something of a surprise. Beckman hopes that the combined companies will give it greater leverage with larger buyers and those seeking a broader array of tests from one supplier.
You may also be interested in...
With Pluck and Luck, Sysmex Tackles Hematology
Sysmex's break in the US with distribution partner Roche frees it to reap the rewards of building its own brand. It's betting that a best-of-breed strategy can help it double revenues by 2006 and increase margins. It's got a stellar reputation but it's in a tough market that doesn't leave much room for error.
With Pluck and Luck, Sysmex Tackles Hematology
Sysmex's break in the US with distribution partner Roche frees it to reap the rewards of building its own brand. It's betting that a best-of-breed strategy can help it double revenues by 2006 and increase margins. It's got a stellar reputation but it's in a tough market that doesn't leave much room for error.
Beckman Coulter's Play for High Growth
With the Coulter integration successful, Beckman Coulter looks for high-growth opportunities outside of its traditional businesses. Beckman, through internal efforts in its life sciences business and a series of small alliances, is making a play in genomics and proteomics. In addition to building up near-term revenues, the aim is to find new "content" in the form of assays for its clinical business.